Metastatic Castration Resistant Prostate Cancer Clinical Trial
Official title:
A Randomised, Double-Blind, Multicentre Phase Ⅲ Study to Evaluate Abiraterone Acetate Versus Placebo Combined With Prednisone in Subjects With Asymptomatic or Mild Symptoms Without Chemotherapy, Metastatic Castration Resistant Prostate Cancer.
Abiraterone acetate is an orally effective CYP17 inhibitor, which is metabolized into abiraterone in the body, and its inhibitory activity against CYP17 is 10-30 times that of ketoconazole. Clinical studies have shown that abiraterone acetate can significantly reduce the level of prostate specific antigen (PSA) in PCa patients, and help to reduce tumors, extending the lifespan of patients with advanced PCa for several years, and the toxicity is acceptable.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02495974 -
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
||
| Completed |
NCT03641560 -
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
|
Phase 4 | |
| Terminated |
NCT02441517 -
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
|
Phase 4 | |
| Active, not recruiting |
NCT03454750 -
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
|
Phase 2 | |
| Completed |
NCT03776968 -
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT02471469 -
Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response
|
||
| Terminated |
NCT03177187 -
Combination Study of AZD5069 and Enzalutamide.
|
Phase 1/Phase 2 | |
| Terminated |
NCT03531827 -
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
|
Phase 2 | |
| Completed |
NCT02566772 -
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT03829436 -
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
|
Phase 1 | |
| Terminated |
NCT05241613 -
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Recruiting |
NCT05369000 -
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02975934 -
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
|
Phase 3 | |
| Active, not recruiting |
NCT04869488 -
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00428220 -
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
N/A | |
| Completed |
NCT03658447 -
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
|
Phase 1/Phase 2 | |
| Terminated |
NCT03042312 -
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
|
Phase 2 | |
| Completed |
NCT02991911 -
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02655822 -
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
|
Phase 1 | |
| Completed |
NCT02426333 -
Optimizing Abiraterone Therapy
|